Table 1 Characteristics of issued iPS cell patents
From: Pluripotent patents make prime time: an analysis of the emerging landscape
Patent no. | Earliest priority;filing date;grant date | Composition/ product claims | Process claims | Listed genes in broadest claims | Related international publications |
|---|---|---|---|---|---|
JP 2008-131577 (Yamanaka) | Dec. 13, 2005;Dec. 6, 2006;Sept. 12, 2008 | No | Yes | Oct 3/4, Klf4, c-Myc and Sox2. | EP1970446, ZA200804673, US20090068742, KR20080095852, JP2009165480, JP2009165479, JP2009165478, JP2008283972, JP4183742, JP2009165481, WO2007069666, EA200870046, CN101356270, CA2632142, AU2006325975, US20090227032, US20090047263, US20100062533 |
GB2450603 (Sakurada) | June 15, 2007;June 13, 2008;Jan. 12, 2010 | No | Yes | Combination of Oct3/4, Klf4 and Sox2 (but not c-Myc) | US20090304646, US20090191159, JP2008307007, WO2009007852, WO2009006997, WO2009006930, AU2008273817 |
US 7,682,828 (Jaenisch) | Nov. 26, 2003;Nov. 24, 2004;March 23, 2010 | Yes | No | Endogenous gene expressed in pluripotent ES cell, required for pluripotency, and downregulated during differentiationExogenous nucleic acid encoding pluripotency protein expressed in pluripotent ESC and downregulated during differentiation | International publications with this priority date not foundWO2008124133 (earliest priority claim April 7, 2007) |
